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Background: Monoclonal antibodies (mAbs) recognizing 
Class III epitope of CD34 are essential for flow cytometric di-
agnosis of leukemia. Methods: 27H2 mAb was developed 
from a mouse alternatively immunized with human acute leu-
kemia cell lines, KG1 and Molm-1. Using flow cytometric 
analysis of various leukemic cell lines and peripheral blood, 
immunohistochemical study of frozen tonsil, we charac-
terized 27H2 mAb. Antigen immunoprecipitated with 27H2 
mAb immunobloted with anti-CD34 mAb. A case of bone 
marrow sample of acute lymphoblastic leukemia (ALL) pa-
tient was obtained at CBNU Hospital. For epitope identi-
fication enzyme treatment with neuraminidase and O-sialo-
glycoprotein endopeptidase (OSGE) and blocking assay with 
known classIII mAb (HPCA-2) were done. Results: Only KG1 
and Molm-1 revealed positive immunoreactivity. Immunohis-
tochemical staining disclosed strong membranous immunor-
eactivity on high endothelial venules. Antigen immunopre-
cipitated by 27H2 mAb showed approximately 100 kDa sized 
band immunoblotted with anti-CD34 under non-reducing 
conditions. Epitope recognized by 27H2 mAb disclosed re-
sistancy to both neuraminidase and OSGE treatment and 
completely blocked with known class III mAb preincubation. 
CD34 positive leukemic cells in BM of pre B cell ALL patient 
detected by FITC-conjugated 27H2 and HPCA-2 were identi-
fied with similar sensitivity. Conclusion: A novel murine mAb 
recognizing class III epitope of human CD34 with high affin-
ity, which is useful for flow cytometric diagnosis of leukemia, 
was developed. 
[Immune Network 2010;10(6):239-246]
INTRODUCTION
The CD34 is a heavily glycosylated transmembrane protein, 
which was expressed on developmentally early hematopoietic 
stem and progenitor cells (1,2) and small-vessel endothelial 
cells  (3-5),  especially  high  endothelial  venules  on  lymph 
nodes. CD34 is used as a marker for leukemia diagnosis and 
subclassification, as a label for quantification of stem/progeni-
tor cells in blood and marrow and as a target for immuno-
logic  purification  of  stem/progenitor  cells  for  clinical  trans-
plantation  (6).  Until  recently  lots  of  mAbs  against  CD34, 
which were mainly established by immunizing leukemic cell 
lines has provided essential roles for structural and functional 
analyses  of  the  CD34  antigen.
    The 5th HLDA workshop approved the three epitopes of 
CD34 on the basis of differential sensitivity of the three epito-
pes  to  the  actions  of  neurminidase  (sialidase  from  Vibrio 
Cholera) and glycoprotease (or endopeptidase from Pasteur-
ella haemolytica) as a standard for the classification of new 
CD34 antibodies. The class I epitope is sensitive to all proteo-
lytic  enzymes  (glycoprotease,  neuraminidase  and  chymopa-
pain). Early established mAbs (My10, BI3C5, 12.8) obtained 
by immunizing relatively undifferentiated leukemic cells are 
included  in  this  category  and  recognize  heavily  O-glycosy-
lated epitopes. The class III epitope is insensitive to all pro-
teolytic enzymes. HPCA-2 (also known as 8G12) mAb avidly 
bind  to  all  glyforms  of  CD34  (7-10).A Novel mAb Recognizing Human CD34 Class III
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    The class II epitope is resistant to neuraminidase, but sensi-
tive glycoprotease. As QBEnd 10 class II mAb recognize de-
n a t u r a t i o n  r e s i s t a n t  e p i t o p e ,  i t  i s  g e n e r a l l y  u s e d  i n  i m -
munopathological diagnosis using paraffin embedded tissues.
  Because leukemia arise from immature hematopoietic pre-
cursor cells during differentiation, CD34 is one of leukemia 
markers for differential diagnosis. About 40% of acute mye-
loid leukemias and 65% of pre-B acute lymphoblastic leuke-
m i a s  e x p r e s s  t h e  C D 3 4  m o l e c u l e ,  w h e r e a s  o n l y  1 ∼5%  of 
acute T-lymphoid leukemias express the CD34 antigen. CD34 
is often expressed on blasts from chronic myeloid leukemia 
patients  in  blast  crisis,  whereas  chronic  phase  cells,  other 
chronic  leukemias  and  lymphomas  of  more  differentiated 
phenotypes are uniformly negative (1,2,11-17). For the flow 
cytometric  detection  of  leukemic  cells  in  leukemia  patient 
class  III  mAbs  are  known  to  be  better  than  class  I  and  II 
mAbs (7,8,18-26). It was reported that at least some class I 
antibodies  fail  to  detect  the  glycoforms  of  CD34  expressed 
some leukemias and leukemic cell lines because lineage com-
mitted progenitors lose their carbohydrate moieties. Further-
more  if  they  are  conjugated  with  negatively  charged  fluo-
rochromes such as FITC their identification rates of leukemic 
cells in patient are markedly reduced below the threshold of 
practical usage. On the contrary unconjugated class III mAbs 
avidly bind to all glycoslated backbone of CD34 (7-10) and 
after  conjugation  with  appropriate  fluorochromes  relatively 
hold  their  high  specificity  and  avidity  for  all  glycosylated 
structures of CD34. So it seems to be that class III mAbs are 
the best reagents of identification of both leukemic cells and 
n o r m a l  B M  s t e m  c e l l s  b y  f l o w  c y t o m e t r i c  a n a l y s i s .
    In this study, we produced a high affinity monoclonal anti-
body (27H2) to CD34 using a new alternative immunization 
strategy and confirmed class III epitope specificity. And we 
also  revealed  a  diagnostic  usefulness  of  FITC  conjugated 
27H2  mAb  in  pre  B  cell  acute  leukemia  patient.
MATERIALS AND METHODS
Animals and reagents
Balb/c mice, 6∼8 weeks old, of either sex, were purchased 
from Daihan animal Corporation (seoul, south Korea). Normal 
peripheral blood in ethylenediaminetetraacetic acid tubes was 
obtained  from  healthy  volunteers.  The  leukemic  cell  lines, 
KG-1,  Molm-1,  Jurkat,  CEM,  Daudi,  TF-1,  IM9  and  Ramos 
were obtained from American Type Culture Collection (ATCC; 
Manassas, VA, USA). Bone marrow cells of acute myeloid leu-
kemia patient and Human frozen tissue were collected from 
the Department of Pathology, Chungbuk National University 
Hospital.  Anti-CD34  (clone  27H2  and  4H11),  anti-CD3,  an-
ti-CD8,  anti-CD19,  anti-CD11b,  anti-CD66c,  anti-CD61  were 
either purchased from DiNona Inc. (clone 27H2 and 4H11, 
South  Korea).  Other  anti-CD34  and  CD59  were  either  pur-
chased  from  BD  Biosciences  (clone  QBEnd  10  and  clone 
HPCA-2).  and  anti-CD120a  was  either  purchased  from 
Department  of  Pathology,  Chungbuk  National  University.
Production of the monoclonal antibody
After  6  week-old  Balb/c  mouse  were  immunized  intra-
peritoneal  (I.P.)  injection  with  Molm-1  and  KG1  cells  per 
mice at 4-2-2 week intervals for 2 month. The unique method 
of immunization was alternatively performed by Molm-1 and 
KG1 leukemic cell line. First Molm-1 cells were injected on 
the first day. 30 days later, Molm-1 cells were injected. Third 
immunized  and  final  boost  were  injected  KG-1  cells.  Test 
bleed was performed in Molm-1 and KG1 by FACS. The hy-
brids by fusion the B cells and myeloma using PEG were se-
lected  in HAT medium.  After  10  days,  culture supernatants 
were harvested and tested for reaction to human lymphocytes 
by  indirect  immunofluorescence  method  using  flow  cyto-
metry.  The  resulting  hybridoma  clone,  whose  supernatant 
was reactive to human lymhpocytes, was named 27H2. Cells 
from 96 well were subcloned by limiting dilution, and the cul-
ture  supernatants  of  the  clones  were  tested  for  antibody 
production. Finally, we established a hybridoma clone, which 
is producing 27H2 monoclonal antibody (DiNonA Inc. Korea).
Immunohistochemistry
Tonsil and thymus frozen tissue sections were obtained from 
the surgical pathology files of Chungbuk National University 
H o s p i t a l  a n d  s c r e e n e d .  T i s s u e s  w e r e  i n c u b a t e d  w i t h  2 7 H 2  
mAb obtained from hybridoma supernatant at 4
oC for over-
night,  thereafter,  were  washed  four  times  with  TBS. 
Sequential incubation was done with biotinylated anti-mouse 
immunoglobulin  (DAKO,  Carpinteria,  USA)  for  10  min  at 
room temperature (RT). Then tissues were washed four times 
again  and  followed  streptavidin-horseradish  peroxidase 
(DAKO, Carpinteria, USA) for 10 min at RT, were washed the 
same. Finally, reaction product was visualized with 3’-diami-
nobenzidine (DAB; Sigma, USA). Counterstain was not per-
formed and the reaction pattern was analyzed based on serial 
hematoxylin-eosin  stained  sections.  Positive  cells  were  de-
fined  by  the  positive  staining  pattern  along  the  cell  mem-A Novel mAb Recognizing Human CD34 Class III
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brane.
Immunoprecipitation and Western blot analysis
1.25×10
7  cells/ml  of  TF-1  cells  and  1.25×10
8  cells/ml  of 
bone marrow cells of acute myeloid leukemia patient were 
lysed with 1 ml of ice-cold lysis buffer (50 mM Tris-Cl, pH 
7.4, 150 mM NaCl, 1% Nonidet P-40; NP40 and 1 mM phe-
nyl-methyl-sulfonyl-fluoride;  PMSF).  For  searching  of  27H2 
mAb recognized antigen, lysates were incubated with 27H2 
mAb and isotype matched control anti-CD120a coated protein 
G sepharose bead for 16∼18 hr at 4
oC. After extensive wash-
ing,  the  immunoprecipitates  were  eluted  by  boiling  for  10 
min with 5×sample buffer and analyzed on 10% SDS-PAGE 
under both non-reduced and reduced conditions. After ele-
trophoretic  transfer  of  the  proteins  to  a  PVDF  (Millipore 
Corporation, USA), the membrane was blocked with 5% skim 
milk in 1×PBS containing 0.02% Tween-20. The membrane 
was incubated with anti-CD34 mAb (4H11), followed by per-
oxidase-conjugated goat anti-mouse Ig (Dako, USA, 1：1,000 
dilution in blocking solution). Immunoreactive proteins were 
visualized using the enhanced chemiluminescence detection 
system  (ECL,  iNtRON).
Enzyme treatments
To  identify  the  epitope  of  CD34  mAb,  TF-1  cells  at  3.5× 
10
6/ml  in  Ca
＋＋/Mg
＋  free  HBSS  (Hank’s  Balanced  Salt 
Solution)cells  were  harvested  and  washed  by  1×PBS  two 
times. Neuraminidase (0.08 U) and O-sialoglycoprotein endo-
peptidase (10 ul) was added to 200 ul total volume. Then, 
cells  were  incubated  for  30  minutes  at  37
oC,  washed  with 
cold  1×PBS  and  stained  with  27H2,  K06  and  QBEnd  10, 
respectively.  Cells  washed  again  and  then  incubated  with 
FITC  conjugated  secondary  antibody  and  analyzed  by  flow 
cytometry (FACSCalibur, BD, USA). K06 and QBEnd 10 were 
used  as  positive  control  mAbs,  respectively.
Blocking study
KG-1 and Molm-1 cells were preincubated with 1, 10 and 20
μg/ml  of  purified  HPCA-2  (BD  Bioscience)  mAbs,  re-
spectively, for 30 min at 4
oC. Then, cells were stained with 
1μg/ml  27H2-FITC  (DiNonA  Inc.  Korea),  incubated  for  15 
min at 4
oC, where samples blocked off the light, washed with 
ice-cold 1×PBS, analyzed using FACSCalibur (Becton-Dickin-
s o n ,  S a n  J o s e ,  C A ) .
Immunofluorescence staining and flow cytometry
Screening  of  cell  surface  antigen  was  recognized  27H2 
(DiNonA Inc. Korea) and HPCA-2 mAb (BD Bioscience) was 
analysis  by  immunofluorescence  staining  and  flow  cytome-
teric analysis. Lymphocytes, monocytes, granulocytes, plate-
lets and RBCs which were isolated from peripheral blood of 
healthy volunteer were obtained and cultured in RPMI 1640 
medium supplemented with 10% fetal calf serum (FCS). The 
indirect immunofluorescence staining was performed by se-
quentially incubating 10
6 cells with saturating amounts of cul-
ture supernatant or 1μg of purified antibody of 27H2 mAb 
or 2.0μg of purified antibody of HPCA-2 mAb, for 20 min 
at  4
oC.  Thereafter,  cells  were  washed  two  times  with  cold 
phosphate-buffered  saline  (PBS)  followed  by  FITC-  or  PE- 
conjugated goat anti-mouse IgG (CALTAG, USA) for 15 min 
at  4
oC  then  cells  were  washed  two  times  with  cold  phos-
phate-buffered saline (PBS). Cells were analyzed with a flow 
cytometer (FACScalibur, BD). The double color staining was 
performed by sequentially incubating 10
6 cells with saturating 
amounts of culture supernatant or 10μg of FITC conjugated 
antibody  of  27H2  and  HPCA-2,  PE  conjugated  antibody  of 
HLA-DR (YG18; DiNona Inc, Korea) mAb, for 20 min at 4
oC. 
Cells were analyzed with a flow cytometer (FACScalibur, BD).
RESULTS
Determination of antibody isotype
The  isotype  of  27H2  mAb  was  determined  by  enzyme  im-
munoassay using mouse immunoglobulin isotyping kit. The 
isotype  of  27H2  mAb  was  IgG1.
Expression patterns of various normal hematopoietic 
cells and leukemic cell lines
To  examine  expression  profiles  of  antigen  recognized  by 
27H2  mAb,  we  performed  flow  cytometric  analysis  against 
normal peripheral blood cells and various kinds of leukemic 
cell lines. Only two KG1 and MOLM1 leukemic cells showed 
strong immunoreactivity with 27H2 mAb, while other Jurkat, 
Molt4, U937, IM9, Ramos, CEM, and Daudi leukemic cells did 
not reveal any immunoreactivity (Table I). None of the ma-
ture hematopoietic cells including lymphocytes, granulocytes, 
platelet and red blood cells were reacted with 27H2 mAb as 
expected  (Table  I).
Tissue distribution patterns of normal lymphoid tissues
To evaluate tissue distribution patterns of antigen recognized A Novel mAb Recognizing Human CD34 Class III
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Figure 1. Immunoreactivity of 27H2
on frozen tonsil. Frozen tonsil sec-
tions were immunohistochemically 
stained with monoclonal antibody 
27H2 and counter-stained with he-
matoxylin. 27H2mAb show strong 
immunoreactivity on endothelial 
cells of high endothelial venules 
(Arrow, A), but mature lymphocytes
(A) and squamous epithelia (Arrow 
head, B) reveal negative immuno-
reactivity (A: ×200, B: ×40).
Table I. Expression profiles of antigen recognized by 27H2 mAb 
on various leukemic cell lines and normal peripheral blood cells
Cell line Origin
27H2 HPCA-2
(% Gated)
KG1 AML 98.15 99.96
Molm-1 Megakaryoblast 89.43 88.18
Jucart T-cell   3.45   2.86
CEM T-cell   6.35   6.98
Daudi B-cell   7.53 16.68
IM9 B-cell   6.05   6.45
Ramos B-cell 11.90   6.44
IM9 B-cell   6.05   6.45
Peripheral blood
Lymphocytes
T lymphocytes   0.11   0
B lymphocytes   0   0.13
Monocytes   0   0
Ganulocytes   0   0
RBCs   0   0
Platelets   0   0
Figure 2. Conformation of antigen recognized by 27H2 mAb as CD34.
For searching of 27H2 mAb recognized antigen, TF-1 cells (lane 1,
2) and Bone marrow cells of acute myeloid leukemia patient (lane
3, 4) were lysed. Lysates were incubated with 27H2 mAb (lane 1, 
3) and isotype matched control anti-CD120a (2, 4) coated protein G 
sepharose bead. The immunoprecipitates were separated by SDS- 
PAGE and electro-blotted with 5% skim milk. Membrane was 
incubated with anti-CD34 mAb (4H11), followed by peroxidase- 
conjugated goat anti-mouse Ig. Immunoreactive proteins were 
visualized using the enhanced chemiluminescence detection system. 
Note discreate band of about 100 kDa sized as expected in lane 1
and 3 (Arrows).
by 27H2 mAb we did immunohistochemical staining. The en-
dothelial cells of small vessels of all frozen tissues tested re-
vealed moderate positive immunoreactivity. Especially, 27H2 
mAb  was  strongly  reacted  on  high  endothelial  venules 
throughout the tonsil (Fig. 1). But all lymphocytes, including 
mature T lymphocytes in interfollicular area, resting B lym-
phocytes in mantle zone, activated B lymphocytes in germinal 
center, and squamous epithelia on tonsil showed negative im-
munoreactivity  (Fig.  1).  27H2  mAb  disclosed  no  immunor-
eactivity on paraffin embedded tonsil tissue section (data not 
shown).
Confirmation of antigen recognized by 27H2 mAb 
as CD34
To  characterize  antigen  recognized  by  27H2  mAb,  we  per-
formed immunoprecipitation in TF-1 cells and bone marrow 
samples of acute myeloid leukemia patient using 27H2 mAb A Novel mAb Recognizing Human CD34 Class III
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Figure 3. Identification of class III epitopes of CD34 by neuraminidase and endopeptidase treatment in TF-1 cells. (A) Identification of epitope
using neuraminidase enzyme treatment. 27H2 showed neuraminidase resistant class II or III epitope, while. K06 revealed neuraminidase sensitive
epitope. (B) Identification of epitope using O-sialoglycoprotein endopeptidase enzyme treatment. 27H2 showed endopeptidase resistant class III 
epitope, while. QBEnd 10 revealed endopeptidase sensitive class II epitope. 
and subsequently did western blot analysis by known CD34 
mAb (4H11, Dinona, Inc). As shown in Fig. 2, Western blot 
d i s c l o s e  d i s c r e t e  b a n d  o f  a n  a p p r o x i m a t e  m o l e c u l a r  w e i g h t 
of 100 kDa as expected in lane 1 and 3 under non-reducing 
condition  (Fig.  2).  So  we  could  show  direct  evidence  that 
2 7 H 2  m A b  c a n  r e c o g n i z e  C D 3 4  a n t i g e n .
Identification of class III epitope of CD34 by neura-
minidase and endopeptidase treatment
To identify the epitope specificity we treated TF-1 cells with 
two kinds of enzymes. Upon treatment with neuraminidase, 
which can cleave sialylated carbohydrate moiety and O-sialo-
glycoprotein  endopeptidase,  which  can  cleave  sialylated 
0-linked glycans residue, both K06 mAb as a positive control 
showed  sensitive  epitope  to  neuraminidase  (Fig.  3A)  and 
QBEnd 10 class II mAb revealed sensitve epitope to endo-
peptidase  (Fig.  3B).  However  epitope  recognized  by  27H2 
mAb was resistant both neuraminidase and O-sialoglycopro-
tein endopeptidase treatment in TF-1 leukemic cells (Fig. 3). 
This results tell us that 27H2 mAb recognize class III epitope 
of  CD34.
Identification of class III epitope of CD34 using 
blocking assay
Whether epitope recognized 27H2 mAb  is blocked  by well 
known mAb (Anti-HPCA-2, BD) against CD34 class III epit-
ope, we performed blocking assay. Pre incubation with an-
ti-HPCA-2 near completely blocked classIII epitopes in dose 
dependent manner, so FITC conjugated 27H2 mAb could not 
bind at all on TF-1 cells under high concentration (Fig. 4). 
This dose dependent inhibition means that two anti-HPCA-2 
and  27H2  mAb  recognize  an  identical  epitope  or  at  least 
shared epitopes. Therefore, we also confirmed that the anti-
body  27H2  recognize  class  III  epitope  of  CD34.A Novel mAb Recognizing Human CD34 Class III
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Figure 5. Comparison with FITC conjugated commercial class III CD34 mAb (Anti-HPCA-2) in bone marrow cells of pre B cell acute lymphoblastic
leukemia patient. Shown are the determinations of leukemic cells from a patient with pre B cell acute lymphoblastic leukemia. Staining was
done with IgG FITC, PE, 27H2-FITC, Anti-HPCA-2-FITC, 4H11-FITC and HLA-DR (YG18)-PE. Note similar sensitivity for detecting leukemic cells
of pre-B cell acute lymphoblastic leukemia patient.
Figure 4. Identification of class III epitopes of CD34 by blocking assay 
with class III anti-HPCA-2 in TF-1 cells. Blocking assay with 
anti-HPCA-2 and 27H2. TF-1 cells were preincubated with various 
amounts of anti-HPCA-2 and then FITC conjugated 27H2 was 
incubated as detection antibody. Note competitive inhibition of class 
III anti-HPCA was definitive. The data are representative of three 
separate experiments performed.
Comparison of CD34 molecule against 27H2 and 
anti-HPCA-2 in bone marrow cells of pre B cell acute 
lymphoblastic leukemia
To evaluate the diagnostic usuage of this 27H2 mAb we ex-
amined the detection sensitivity of class III epitope on leuke-
mic cells of pre B ALL patient using FITC conjugated commer-
cial mAbs, anti-HPCA-2, and FITC conjugated 27H2 mAb by 
flow cytometric analysis. We confirmed that both 27H2 and 
Anti-HPCA-2  epitopes  revealed  similar  detection  sensitivity 
and affinity on pre B ALL (Fig. 5). The average percentage 
of  detecting  CD34  positive  leukemic  cells  in  bone  marrow 
sample using 27H2 and anti-HPCA-2 mAb was equivalent to 
95%.
DISCUSSION
In this report we produced a high affinity monoclonal anti-
body (27H2) to CD34 using a new alternative immunization 
strategy and confirmed that 27H2 recognized class III epitope 
of CD34 showing resistancy to neuraminidase and endopepti-
dase  treatment  and  inhibition  with  well  known  CD34  class 
III  mAb  (HPCA-2).
    Complexity of glycoslyation along differential stage of hem-
atopoietic progenitor cells and differently glycosylated status 
of leukemic cells can generate many conformation dependent 
novel epitopes of CD34. So, new mAbs recognizing novel dif-
ferent epitopes is still needed for further clarification of CD34 
structure and function. In order to establish more appropriate 
mAb against CD34 in flow cytometric diagnosis of leukemia, 
we planed alternative cellular immunization method. On the 
hypothesis that if we alternatively immunize KG1 and Molm1, 
which  express  high  level  of  CD34,  chance  to  obtain  mAbs 
recognizing more common conformation dependent epitopes 
of CD34 (probably class III epitope) would be increased. We 
screened and picked up hybridoma clones which are produc-
ing  mAbs  which  reveal  positive  immunoreactivity  to  both 
KG1 and Molm1 but negative normal PBMC. Among several 
clones selected 27H2 showed most high mean fluorescent in-
tensity  in  flow  cytometric  analysis.  In  addition,  27H2  mAb A Novel mAb Recognizing Human CD34 Class III
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was not reacted with platelets, monocytes, granulocytes, lym-
phocytes, and erythrocytes as expected (data not shown). In 
the case of various leukemic cell lines, only KG1 (acute mye-
logenous  leukemia)  and  Moml-1  (megakaryoblast)  revealed 
strong immunoreactivity with 27H2, but other T and B leuke-
mic  cell  lines  were  not  reacted  with  27H2  (Table  I). 
Sensitivity and specificity studies to detect CD34 positive leu-
kemic cells compared with commercial CD34 mAb (HPCA-2) 
were  achieved  (Table  I).
    Immunoreactivity  on  frozen  tonsil  section  by  27H2  mAb 
disclosed strong positivity on high endothelial venules as ex-
pected, while all mature and actvated lymphocytes and squ-
amous epithelia revealed negative immunoreactivity (Fig. 1). 
Due to narrow tissue distribution patterns of CD34 antigen, 
only positive on small blood vessels in tissue section, this im-
munohistochemical staing results and above negative normal 
blood cell expression patterns strongly support the possibility 
that 27H2 mAb can recognize CD34. Furthermore 27H2 mAb 
failed  to  detect  formalin  fixed  paraffin  embedded  CD34 
antigen. As only mAb (eg. QBEnd 10) recognizing CD34 class 
II epitope can detect paraffin embedded CD34, these finding 
indirectly  support  27H2mAb  can  recognize  CD34  class  I  or 
class  III  epitope  other  than  classII.
    Nextly by perfoming immunoprecipitation with 27H2 mAb 
and subsequently did Western blotting by known CD34 mAb, 
we could disclose direct evidence that antigen recognized by 
27H2  mAb  seems  to  be  CD34  (Fig.  2).
    Sutherland  et  al.  (27)  reviewed  structural  and  functional 
features of the CD34 antigen and definitively showed academ-
ical and clinical importance of different mAbs against CD34. 
Because epitope specificity of mAbs against CD34 determines 
their specific clinical and research usage, identification of spe-
cific  epitope  is  inevitable  step.  Standard  of  epitope  classi-
fication was adopted by the 5th HLDA workshop. MAbs to 
epitopes sensitive to both sialidase and glycopeptidase des-
ignated class I (BI.3C5) and mAbs resistant to both enzyme 
designated class III (HPCA-2). MAbs (QBEnd 10) against epit-
ope  sensitive  to  glycopeptidase,  but  resistant  to  neuramini-
dase defined class II. In this study the epitope recognized by 
27H2  was  resistant  by  neuraminidase  and  endopeptidase 
treatment  (Fig.  3)  and  completely  blocked  with  known 
classIII mAb (HPCA-2) (Fig. 4), so it was evident that 27H2 
recognize  class  III  epitope  of  CD34.
    For the fluocytometric detection of leukemic cells in leuke-
mia patient class III mAbs are known to be better than class 
I and II mAbs (7,8,18-26). At least three factors involved are 
firstly charge of the epitope, secondly avidity between epit-
ope  and  mAbs  and  lastly  glycosylated  status  of  epitope.  It 
was reported that at least some class I antibodies fail to detect 
the glycoforms of CD34 expressed some leukemias and leu-
kemic cell lines because lineage committed progenitors lose 
their  carbohydrate  moieties.  Furthermore,  if  they  are  con-
jugated with negatively charged fluorochrome such as FITC 
and their identification rates of leukemic cells in patient are 
m a r k e d l y  r e d u c e d  b e l o w  t h e  t h r e s h o l d  o f  p r a c t i c a l  u s a g e .  
Class II mAb-FITC conjugates no longer bind with high affin-
ity due to charge constraints (7,23). On the contrary uncon-
jugated class III mAbs avidly bind to all glycosylated back-
bone of CD34 (7-10) and after conjugation with appropriate 
fluorochromes relatively hold their high specificity and avidity 
for all glycosylated structures of CD34. It was also reported 
that class III (HPCA-2)-FITC detected a large number of CD34 
positive leukemic cells in normal marrow and acute leukemia 
samples than class II (QBEnd 10)-FITC conjugates (7,8,18-22). 
So it seems to be widely accepted that CD34 class III mAbs 
are the best reagents of identification of both leukemic cells 
a n d  n o r m a l  B M  s t e m  c e l l s  b y  f l o w  c y t o m e t r i c  a n a l y s i s .  A s  
FITC conjugated 27H2 disclosed similar sensitivity (95%) and 
affinity (Fig. 5) compared with widely used commercial class 
III (HPCA-2)-FITC in pre B cell acute leukemia patient, 27H2 
class  III  mAb  can  be  clinically  used  as  a  useful  diagnostic 
reagent.
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